Jelena Kornej (Heart Centre, University of Leipzig, Saxony) discusses the LIFE-Adult-Study, a population-based cohort study including 10,000 participants from Leipzig and eastern Germany. The study was initiated and conducted by the Leipzig Research Centre for Civilisation Diseases (LIFE), and the main objective was to analyse the prevalence, genetic predisposition and early-onset markers as well as the lifestyle factors for civilisation diseases such as heart function vascular diseases and metabolic diseases as well as dementia, sleep disorders, allergies and more. Dr Kornej then goes on to discuss her work on whether PR interval prolongation could be considered an intermediate phenotype towards atrial fibrillation.
Filmed at EHRA 2018, Barcelona.
1. What was the background and rationale behind the LIFE-Adult-Study? 0:07
2. What were the key findings you presented at this meeting? 1:32
3. What are the next steps in this area of research over the coming years? 3:07
Share this Video
Related Videos In Atrial Fibrillation
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Hugh Calkins, AF Symposium 2021: the STOP Persistent AF Clinical Trial
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841). Questions: Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13) What were the findings of the study? (0.43) What are their implications for clinical practice? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!